SKP has reported robust H1 2015 results with operating profit excluding milestones 118% ahead of H1 2014. flutiform® is generating strong in-market growth (129% in H1 2015 vs. H1 2014) as it continues to gain market share and benefit from encouraging growth in demand. We upgrade FY 2015 and 2016 PBT forecasts to reflect flutiform®’s strong performance. Our revised valuation, now DCF and NPV based, offers significant upside at 422p intrinsic value per share (from 374p). We also evaluate a blue sk ....
26 Aug 2015
flutiform® ahead of expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
flutiform® ahead of expectations
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
26 Aug 2015 -
Author:
N+1 Singer Team -
Pages:
13
SKP has reported robust H1 2015 results with operating profit excluding milestones 118% ahead of H1 2014. flutiform® is generating strong in-market growth (129% in H1 2015 vs. H1 2014) as it continues to gain market share and benefit from encouraging growth in demand. We upgrade FY 2015 and 2016 PBT forecasts to reflect flutiform®’s strong performance. Our revised valuation, now DCF and NPV based, offers significant upside at 422p intrinsic value per share (from 374p). We also evaluate a blue sk ....